|
|
|
|
|
Last Trade
|
Last Trade:
$22.49
|
Change:
0.15 (0.67%)
|
Trade Time:
Mar 30
|
Market Cap:
$1.15B
|
|
|
|
|
|
|
Description of Business
|
|
We are a biopharmaceutical company with peptide-based new chemical entities
rusfertide and JNJ-2113 (formerly known as PN-235) in different stages of
development, all derived from our proprietary discovery technology platform. Our
clinical programs fall into two broad categories of diseases; (i) hematology and
blood disorders, and (ii) inflammatory and immunomodulatory diseases.
Figure 1: Our Product Pipeline
[[Image Removed: Graphic]]
Rusfertide
Our most advanced clinical asset, rusfertide (generic name for PTG-300), is an
injectable hepcidin mimetic in development for the potential treatment of
erythrocytosis, iron overload and other blood disorders and is wholly owned.
Hepcidin is a key hormone in regulating iron equilibrium and is critical to the
proper development of red blood cells. Rusfertide mimics the effect of the
natural hormone hepcidin, but with greater potency, solubility and stability.
|
|
|
|